Streetbeat News

Analyst Ratings

CADE

In the last quarter, Cadence Bank (NYSE:CADE) received 2 bullish, 3 somewhat bullish, and 2 indifferent ratings from analysts. The average price target is $25.71, indicating an upside from the current price of $19.88. However, this average has decreased by 8.18% from the previous average price target of $28.00.

Portfolio Pulse from Benzinga Insights

June 29, 2023 | 7:00 pm

FHB

First Hawaiian (NASDAQ:FHB) has received indifferent ratings from five analysts in the last quarter, with an average price target of $23.8, implying an upside from the current price of $18.015. This average price target represents a 7.03% decrease from the previous average price target of $25.60.

Portfolio Pulse from Benzinga Insights

June 29, 2023 | 7:00 pm

ONCY

Five analysts have given bullish ratings for Oncolytics Biotech (NASDAQ:ONCY) in the last quarter, with an average price target of $11.8, implying significant upside from the current price of $2.66. This average price target has decreased by 21.33% from the previous average of $15.00.

Portfolio Pulse from Benzinga Insights

June 29, 2023 | 7:00 pm

GPK

In the last quarter, Graphic Packaging Holding (NYSE:GPK) received two bullish, one somewhat bullish, and one indifferent rating from four analysts. The average price target is $30.5, implying an upside from the current price of $23.505. This average has increased by 0.83% from the previous average price target of $30.25.

Portfolio Pulse from Benzinga Insights

June 29, 2023 | 7:00 pm

LVS

A significant bullish stance has been taken on Las Vegas Sands (NYSE:LVS) by a large investor, as indicated by unusual options activity. The sentiment among these big-money traders is 60% bullish and 40% bearish. The whales have been targeting a price range from $45.0 to $67.5 for Las Vegas Sands over the last 3 months. Jefferies has downgraded its action to Hold with a price target of $65, while JP Morgan maintains their Overweight rating with a price target of $72.

Portfolio Pulse from Benzinga Insights

June 29, 2023 | 6:49 pm

ELV

A whale investor has taken a bearish stance on Elevance Health (NYSE:ELV), with 81% of the spotted trades being bearish. The whale has been targeting a price range from $430.0 to $480.0 for Elevance Health over the last 3 months. The current price of ELV is $439.31, up 0.5%. Truist Securities maintains a Buy rating on Elevance Health with a price target of $560.

Portfolio Pulse from Benzinga Insights

June 29, 2023 | 6:49 pm

T

A significant amount of unusual options activity has been observed for AT&T (NYSE:T), with a split sentiment of 50% bullish and 50% bearish among big-money traders. The options trades have targeted a price range from $3.0 to $34.0 for AT&T over the last 3 months. HSBC has maintained their Buy rating on AT&T with a price target of $19, while MoffettNathanson upgraded its action to Market Perform with a price target of $17.

Portfolio Pulse from Benzinga Insights

June 29, 2023 | 6:49 pm

AREC

H.C. Wainwright analyst Heiko F. Ihle reiterated a Buy rating on American Resources Corporation (AREC) with a price target of $3.50. AREC recently rejected an unsolicited bid for the assets of its metallurgical carbon division, American Carbon. The analyst believes AREC is well-funded to continue growing its operations and expand production at its McCoy Elkhorn and Wyoming County assets. AREC is also considering a lithium and critical mineral refining operation, which could supply domestic battery manufacturers.

Portfolio Pulse from Nabaparna Bhattacharya

June 29, 2023 | 6:30 pm

MRCY

Mercury Systems Inc (NASDAQ:MRCY) has appointed David Farnsworth as CFO, effective July 17, 2023. Farnsworth was previously the CFO of HawkEye 360. The company also announced the appointment of Roger Krone as an independent director, effective June 28, 2023. MRCY shares are trading higher by 2.13% at $33.57.

Portfolio Pulse from Shivani Kumaresan

June 29, 2023 | 6:23 pm

RNXT

RenovoRx Inc (NASDAQ:RNXT) presented new data from its Phase 3 TIGeR-PaC study of RenovoGem in advanced pancreatic cancer at the 2023 ESMO World Congress on Gastrointestinal Cancer. The interim analysis showed an eight-month median progression-free survival (PFS) benefit for patients treated with RenovoGem compared to standard care. The TIGeR-PaC Data Monitoring Committee found the interim data promising and recommended the continuation of the trial. RNXT shares are up 8.93% at $2.44.

Portfolio Pulse from Vandana Singh

June 29, 2023 | 6:09 pm